TEST BANK
Pßarmacology Illustrated Revievs
8th Edition Whalen Test Bank
TEST BANK
, Pharmacology Illustrated Reviews 8th Edition Whalen Test Bank
TABLE OF CONTENT
Chapter 1: Pharmacokinetics
Chapter 2: Drug–Receptor Interactions and Pharmacodynamics
Chapter 3: The Autonomic Nervous System
Chapter 4: Cholinergic Agonists
Chapter 5: Cholinergic Antagonists
Chapter 6: Adrenergic Agonists
Chapter 7: Adrenergic Antagonists
Chapter 8: Drugs for Neurodegenerative Diseases
Chapter 9: Anxiolytic and Hypnotic Drugs
Chapter 10: Antidepressants
Chapter 11: Antipsychotic Drugs
Chapter 12: Drugs for Epilepsy
Chapter 13: Anesthetics
Chapter 14: Opioids
Chapter 15: Drugs of Abuse
Chapter 16: CNS Stimulants
Chapter 17: Antihypertensives
Chapter 18: Diuretics
Chapter 19: Heart Failure
Chapter 20: Antiarrhythmics
Chapter 21: Antianginal Drugs
Chapter 22: Anticoagulants and Antiplatelet Agents
Chapter 23: Drugs for Hyperlipidemia
Chapter 24: Pituitary and Thyroid
Chapter 25: Drugs for Diabetes
Chapter 26: Estrogens and Androgens
Chapter 27: Adrenal Hormones
Chapter 28: Drugs for Obesity
Chapter 29: Drugs for Disorders of the Respiratory System
Chapter 30: Antihistamines
Chapter 31: Gastrointestinal and Antiemetic Drugs
Chapter 32: Drugs for Urologic Disorders
Chapter 33: Drugs for Anemia
Chapter 34: Drugs for Dermatologic Disorders
Chapter 35: Drugs for Bone Disorders
Chapter 36: Anti-inflammatory, Antipyretic, and Analgesic Agents
Chapter 37: Principles of Antimicrobial Therapy
Chapter 38: Cell Wall Inhibitors
Chapter 39: Protein Synthesis Inhibitors
Chapter 40: Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics
Chapter 41: Antimycobacterial Drugs
Chapter 42: Antifungal Drugs
Chapter 43: Antiprotozoal Drugs
Chapter 44: Anthelmintic Drugs
Chapter 45: Antiviral Drugs
Chapter 46: Anticancer Drugs
Chapter 47: Immunosuppressants
Chapter 48: Clinical Toxicology
, Page 1 of 507
Pharmacology fIllustrated fReviews f8th fEdition fWhalen
f Test fBank
Chapter f1: fPharmacokinetics
MULTIPLE fCHOICE
f
1. Which fdrugs fwill fgo fthrough fa fpharmaceutic fphase fafter fit fis fadministered?
a. Intramuscular f cephalosporins
b. Intravenous fvasopressors
c. Oral fanalgesics
d. Subcutaneous fantiglycemics
ANS: fC
f
When fdrugs fare fadministered fparenterally, fthere fis fno fpharmaceutic fphase, fwhich foccurs fwhen fa
f drug fbecomes fa fsolution fthat fcan fcross fthe fbiologic fmembrane.
DIF: fCOGNITIVE fLEVEL: fUnderstanding f(Comprehension) fREF: fdm f3
f TOP: fNURSING fPROCESS: fAssessment
MSC: fNCLEX: fPhysiological fIntegrity: fPharmacological fand fParenteral fTherapies
2. The fnurse fis fpreparing fto fadminister fan foral fmedication fand fwants fto fensure fa frapid fdrug
f action. fWhich fform fof fthe fmedication fwill fthe fnurse fadminister?
a. Capsule
b. Enteric-coated fpill
c. Liquid fsuspension
d. Tablet
ANS: fC
f
Liquid fdrugs fare falready fin fsolution, fwhich fis fthe fform fnecessary ffor fabsorption fin fthe fGI
tract. fThe fother fforms fmust fdisintegrate finto fsmall fparticles fand fthen fdissolve fbefore fbeing
f
f absorbed.
DIF: fCOGNITIVE fLEVEL: fUnderstanding f(Comprehension) fREF: fdm f3
f TOP: fNURSING fPROCESS: fNursing fIntervention
MSC: fNCLEX: fPhysiological fIntegrity: fPharmacological fand fParenteral fTherapies
Page f 1 f of f 507
, Stuvia.com – The Marketplace to Buy and Sell your Study
3. The fnurse fis fteaching fa fpatient fwho fwill fbe fdischarged fhome fwith fa fprescription ffor fan fenteric-
f coated ftablet. fWhich fstatement fby fthe fpatient findicates funderstanding fof fthe fteaching?
a. I fmay fcrush fthe ftablet f and fput fit fin fapplesauce fto fimprove fabsorption.
b. I fshould fconsume facidic ffoods fto fenhance fabsorption fof fthis fmedication.
c. I fshould fexpect fa fdelay fin fonset fof fthe fdrugs feffects fafter ftaking fthe ftablet.
d. I fshould ftake fthis fmedication fwith fhigh-fat ffoods fto fimprove fits faction.
f ANS: fC
Enteric-coated ftablets fresist fdisintegration fin fthe facidic fenvironment fof fthe fstomach fand
f disintegrate fwhen fthey freach fthe fsmall fintestine. fThere fis fusually fsome fdelay fin fonset fof factions
f after ftaking fthese fmedications. fEnteric-coated ftablets fshould fnot fbe fcrushed for fchewed, fwhich
f would falter fthe ftime fand flocation fof fabsorption. fAcidic ffoods fwill fnot fenhance fthe fabsorption fof
f the fmedication. fThe fpatient fshould fnot fto feat fhigh-fat ffood fbefore fingesting fan fenteric-coated
f tablet, fbecause fhigh-fat ffoods fdecrease fthe fabsorption frate.
DIF: fCOGNITIVE fLEVEL: fApplying f(Application) fREF: fdm f3
f TOP: fNURSING fPROCESS: fNursing fIntervention
MSC: fNCLEX: fPhysiological fIntegrity: fPharmacological fand fParenteral fTherapies
4. A fpatient fwho fis fnewly fdiagnosed fwith ftype f1 fdiabetes fmellitus fasks fwhy finsulin fmust fbe
f given fby fsubcutaneous finjection finstead fof fby fmouth. fThe fnurse fwill fexplain fthat fthis fis
f because
a. absorption fis fdiminished fby fthe ffirst-pass feffects fin fthe fliver.
b. absorption fis ffaster fwhen finsulin fis fgiven fsubcutaneously.
c. digestive fenzymes fin fthe fgastrointestinal ftract fprevent fabsorption.
d. the foral fform fis fless fpredictable fwith fmore fadverse feffects.
f ANS: fC
Insulin, fgrowth fhormones, fand fother fprotein-based fdrugs fare fdestroyed fin fthe fsmall fintestine fby
f digestive fenzymes fand fmust fbe fgiven fparenterally. fBecause finsulin fis fdestroyed fby fdigestive
f enzymes, fit fwould fnot fmake fit fto fthe fliver ffor fmetabolism fwith fa ffirst-pass feffect. fSubcutaneous
f tissue fhas ffewer fblood fvessels, fso fabsorption fis fslower fin fsuch ftissue. fInsulin fis fgiven
f subcutaneously fbecause fit fis fdesirable fto fhave fit fabsorb fslowly.
DIF: fCOGNITIVE fLEVEL: fUnderstanding f(Comprehension) fREF: fdm f3
f TOP: fNURSING fPROCESS: fNursing fIntervention: fPatient fTeaching
MSC: fNCLEX: fPhysiological fIntegrity: fPharmacological fand fParenteral fTherapies
Nursedocs Page 2 of 507
Pßarmacology Illustrated Revievs
8th Edition Whalen Test Bank
TEST BANK
, Pharmacology Illustrated Reviews 8th Edition Whalen Test Bank
TABLE OF CONTENT
Chapter 1: Pharmacokinetics
Chapter 2: Drug–Receptor Interactions and Pharmacodynamics
Chapter 3: The Autonomic Nervous System
Chapter 4: Cholinergic Agonists
Chapter 5: Cholinergic Antagonists
Chapter 6: Adrenergic Agonists
Chapter 7: Adrenergic Antagonists
Chapter 8: Drugs for Neurodegenerative Diseases
Chapter 9: Anxiolytic and Hypnotic Drugs
Chapter 10: Antidepressants
Chapter 11: Antipsychotic Drugs
Chapter 12: Drugs for Epilepsy
Chapter 13: Anesthetics
Chapter 14: Opioids
Chapter 15: Drugs of Abuse
Chapter 16: CNS Stimulants
Chapter 17: Antihypertensives
Chapter 18: Diuretics
Chapter 19: Heart Failure
Chapter 20: Antiarrhythmics
Chapter 21: Antianginal Drugs
Chapter 22: Anticoagulants and Antiplatelet Agents
Chapter 23: Drugs for Hyperlipidemia
Chapter 24: Pituitary and Thyroid
Chapter 25: Drugs for Diabetes
Chapter 26: Estrogens and Androgens
Chapter 27: Adrenal Hormones
Chapter 28: Drugs for Obesity
Chapter 29: Drugs for Disorders of the Respiratory System
Chapter 30: Antihistamines
Chapter 31: Gastrointestinal and Antiemetic Drugs
Chapter 32: Drugs for Urologic Disorders
Chapter 33: Drugs for Anemia
Chapter 34: Drugs for Dermatologic Disorders
Chapter 35: Drugs for Bone Disorders
Chapter 36: Anti-inflammatory, Antipyretic, and Analgesic Agents
Chapter 37: Principles of Antimicrobial Therapy
Chapter 38: Cell Wall Inhibitors
Chapter 39: Protein Synthesis Inhibitors
Chapter 40: Quinolones, Folic Acid Antagonists, and Urinary Tract Antiseptics
Chapter 41: Antimycobacterial Drugs
Chapter 42: Antifungal Drugs
Chapter 43: Antiprotozoal Drugs
Chapter 44: Anthelmintic Drugs
Chapter 45: Antiviral Drugs
Chapter 46: Anticancer Drugs
Chapter 47: Immunosuppressants
Chapter 48: Clinical Toxicology
, Page 1 of 507
Pharmacology fIllustrated fReviews f8th fEdition fWhalen
f Test fBank
Chapter f1: fPharmacokinetics
MULTIPLE fCHOICE
f
1. Which fdrugs fwill fgo fthrough fa fpharmaceutic fphase fafter fit fis fadministered?
a. Intramuscular f cephalosporins
b. Intravenous fvasopressors
c. Oral fanalgesics
d. Subcutaneous fantiglycemics
ANS: fC
f
When fdrugs fare fadministered fparenterally, fthere fis fno fpharmaceutic fphase, fwhich foccurs fwhen fa
f drug fbecomes fa fsolution fthat fcan fcross fthe fbiologic fmembrane.
DIF: fCOGNITIVE fLEVEL: fUnderstanding f(Comprehension) fREF: fdm f3
f TOP: fNURSING fPROCESS: fAssessment
MSC: fNCLEX: fPhysiological fIntegrity: fPharmacological fand fParenteral fTherapies
2. The fnurse fis fpreparing fto fadminister fan foral fmedication fand fwants fto fensure fa frapid fdrug
f action. fWhich fform fof fthe fmedication fwill fthe fnurse fadminister?
a. Capsule
b. Enteric-coated fpill
c. Liquid fsuspension
d. Tablet
ANS: fC
f
Liquid fdrugs fare falready fin fsolution, fwhich fis fthe fform fnecessary ffor fabsorption fin fthe fGI
tract. fThe fother fforms fmust fdisintegrate finto fsmall fparticles fand fthen fdissolve fbefore fbeing
f
f absorbed.
DIF: fCOGNITIVE fLEVEL: fUnderstanding f(Comprehension) fREF: fdm f3
f TOP: fNURSING fPROCESS: fNursing fIntervention
MSC: fNCLEX: fPhysiological fIntegrity: fPharmacological fand fParenteral fTherapies
Page f 1 f of f 507
, Stuvia.com – The Marketplace to Buy and Sell your Study
3. The fnurse fis fteaching fa fpatient fwho fwill fbe fdischarged fhome fwith fa fprescription ffor fan fenteric-
f coated ftablet. fWhich fstatement fby fthe fpatient findicates funderstanding fof fthe fteaching?
a. I fmay fcrush fthe ftablet f and fput fit fin fapplesauce fto fimprove fabsorption.
b. I fshould fconsume facidic ffoods fto fenhance fabsorption fof fthis fmedication.
c. I fshould fexpect fa fdelay fin fonset fof fthe fdrugs feffects fafter ftaking fthe ftablet.
d. I fshould ftake fthis fmedication fwith fhigh-fat ffoods fto fimprove fits faction.
f ANS: fC
Enteric-coated ftablets fresist fdisintegration fin fthe facidic fenvironment fof fthe fstomach fand
f disintegrate fwhen fthey freach fthe fsmall fintestine. fThere fis fusually fsome fdelay fin fonset fof factions
f after ftaking fthese fmedications. fEnteric-coated ftablets fshould fnot fbe fcrushed for fchewed, fwhich
f would falter fthe ftime fand flocation fof fabsorption. fAcidic ffoods fwill fnot fenhance fthe fabsorption fof
f the fmedication. fThe fpatient fshould fnot fto feat fhigh-fat ffood fbefore fingesting fan fenteric-coated
f tablet, fbecause fhigh-fat ffoods fdecrease fthe fabsorption frate.
DIF: fCOGNITIVE fLEVEL: fApplying f(Application) fREF: fdm f3
f TOP: fNURSING fPROCESS: fNursing fIntervention
MSC: fNCLEX: fPhysiological fIntegrity: fPharmacological fand fParenteral fTherapies
4. A fpatient fwho fis fnewly fdiagnosed fwith ftype f1 fdiabetes fmellitus fasks fwhy finsulin fmust fbe
f given fby fsubcutaneous finjection finstead fof fby fmouth. fThe fnurse fwill fexplain fthat fthis fis
f because
a. absorption fis fdiminished fby fthe ffirst-pass feffects fin fthe fliver.
b. absorption fis ffaster fwhen finsulin fis fgiven fsubcutaneously.
c. digestive fenzymes fin fthe fgastrointestinal ftract fprevent fabsorption.
d. the foral fform fis fless fpredictable fwith fmore fadverse feffects.
f ANS: fC
Insulin, fgrowth fhormones, fand fother fprotein-based fdrugs fare fdestroyed fin fthe fsmall fintestine fby
f digestive fenzymes fand fmust fbe fgiven fparenterally. fBecause finsulin fis fdestroyed fby fdigestive
f enzymes, fit fwould fnot fmake fit fto fthe fliver ffor fmetabolism fwith fa ffirst-pass feffect. fSubcutaneous
f tissue fhas ffewer fblood fvessels, fso fabsorption fis fslower fin fsuch ftissue. fInsulin fis fgiven
f subcutaneously fbecause fit fis fdesirable fto fhave fit fabsorb fslowly.
DIF: fCOGNITIVE fLEVEL: fUnderstanding f(Comprehension) fREF: fdm f3
f TOP: fNURSING fPROCESS: fNursing fIntervention: fPatient fTeaching
MSC: fNCLEX: fPhysiological fIntegrity: fPharmacological fand fParenteral fTherapies
Nursedocs Page 2 of 507
